Advertisment Nexovas Cilnidipine
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:304

Official publication of the Indian Society of Nephrology
Ahead of Print

Reset osmostat: Facts and controversies

 Department of Physiology, University Institute of Hospital Italiano de Buenos Aires, Argentina

Correspondence Address:
CG Musso,
Department of Physiology, University Institute of Hospital Italiano De Buenos Aires, Potosí 4234, C1199ACL. Ciudad de Buenos Aires
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-4065.254181

Reset osmostat (RO) consists of a change in the normal plasma osmolality threshold (reduction or increase), which consequently induces chronic dysnatremia (hyponatremia or hypernatremia). Although the early papers on RO state that hyponatremic patients with this condition are usually not symptomatic, the current view is that most patients with hyponatremia are symptomatic and should be treated. RO has been associated with a myriad of clinical conditions and has clear diagnostic criteria which are crucial to arrive at the correct diagnosis and treatment.

Print this article
  Search Pubmed for
    -  Feder J
    -  Gomez J M
    -  Serra-Aguirre F
    -  Musso C G
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded12    

Recommend this journal

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07